Efficacy and safety of herbal medicine (Dangguijagyag-san) for primary dysmenorrhea: study protocol for a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial

被引:4
|
作者
Woo, Hye Lin [1 ]
Ji, Hae Ri [1 ]
Kim, Siin [2 ]
Suh, Hae Sun [2 ]
Kim, Kwan-Il [3 ]
Lee, Jin Moo [4 ]
Park, Kyoung Sun [5 ,6 ]
机构
[1] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, Seoul, South Korea
[2] Pusan Natl Univ, Coll Pharm, Busan, South Korea
[3] Kyung Hee Univ, Coll Korean Med, Dept Internal Med, Div Allergy Immune & Resp Syst, Seoul, South Korea
[4] Kyung Hee Univ, Coll Korean Med, Dept Korean Med Obstet & Gynecol, Seoul, South Korea
[5] Jaseng Hosp Korean Med, 536 Gangnam Daero, Seoul 06110, South Korea
[6] Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul, South Korea
关键词
Dangguijagyag-san; Dangguishaoyao-san primary dysmenorrhea; Randomized controlled trial; Protocol; TRADITIONAL CHINESE MEDICINE; QUALITY-OF-LIFE; PREVALENCE; WOMEN; QUESTIONNAIRE; DIAGNOSIS;
D O I
10.1016/j.imr.2020.02.002
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Dangguijagyag-san, also known as Dangguishaoyao-san in Chinese and Toki-shakuyakui-san in Japanese, has been frequently used to treat symptoms associated with dysmenorrhea. The purpose of this trial is to evaluate the efficacy and safety of the herbal medicine, Dangguijagyag-san, relative to those of active control, Gamisoyo-san, and a placebo control for primary dysmenorrhea. Methods: This protocol details a randomized, double-blind, parallel-group, multi-center, investigator-initiated, controlled trial evaluating treatment of primary dysmenorrhea. Two hundred and forty participants will be randomly divided into one of three groups: 1) the Dangguijagyag-san experimental group (EG) (n = 105), 2) the Gamisoyo-san active control group (ACG) (n = 30), and 3) the placebo control group (PCG) (n = 105). The interventions will be administered for two menstrual cycles, and the follow-up will be carried out for the following six menstrual cycles. The primary outcomes are difference in response rates between the EG and the ACG (non-inferiority comparison) and difference in changes from baseline in average pain intensity measured by the visual analogue scale between the EG and PCG (superiority comparison). The secondary outcomes are pain scores derived from pain assessment tools (verbal multidimensional scoring system, retrospective symptom scale, and short form McGill pain questionnaire), dosage of analgesics, pattern diagnosis questionnaires, and short form 36 health survey. Adverse events and vital signs will be checked at every visit, and laboratory tests will be performed for safety evaluation. Discussion: The results of this clinical trial will offer evidence for the efficacy and safety of Dangguijagyag-san for primary dysmenorrhea. (C) 2020 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] The Efficacy and Safety of a Chinese Herbal Product (Xiao-Feng-San) for the Treatment of Refractory Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial
    Cheng, Hui-Man
    Chiang, Leih-Chin
    Jan, Ya-Min
    Chen, Guang-Wei
    Li, Tsai-Chung
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2011, 155 (02) : 141 - 148
  • [32] Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial
    Yu, Shengyuan
    Ran, Ye
    Xiao, Wei
    Tang, Wenjing
    Zhao, Jianjun
    Chen, Wei
    Zhuang, Huikui
    Ouyang, Cun
    Lin, Hai
    Liu, Dequan
    Chen, Tongjun
    Huang, Hui
    Wang, Baoshen
    Hao, Yanlei
    Yan, Zhongrui
    Zhao, Shike
    Wang, Yanling
    Ni, Jinjun
    Wang, Chaodong
    Ding, Wentao
    Li, Guoqian
    Cao, Jianhua
    Tian, Shujuan
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2019, 19 (01):
  • [33] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial
    Ye Yong-an
    Li Xiao-ke
    Zhou Da-qiao
    Chi Xiao-ling
    Li Qin
    Wang Li
    Lu Bing-jiu
    Mao De-wen
    Wu Qi-kai
    Wang Xian-bo
    Zhang Ming-xiang
    Xue Jing-dong
    Li Yong
    Lu Wei
    Guo Jian-chun
    Jiang Feng
    Zhang Xin-wei
    Du Hong-bo
    Yang Xian-zhao
    Guo Hui
    Gan Da-nan
    Li Zhi-guo
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2018, 24 (09) : 653 - 660
  • [34] Shuhe granule for insomnia: study protocol for a double-blind, randomized, placebo-controlled trial
    Gao, Yu
    Chen, Xiangbin
    Li, Yuxi
    Shen, Yuchuan
    Chen, Xinyi
    Xu, Qing
    Peng, Mengling
    Xu, Wen
    Yuan, Jiamin
    Hu, Yuanyuan
    Chen, Xiankun
    Xu, Biyun
    Yang, Zhimin
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [35] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial
    Yong-an Ye
    Xiao-ke Li
    Da-qiao Zhou
    Xiao-ling Chi
    Qin Li
    Li Wang
    Bing-jiu Lu
    De-wen Mao
    Qi-kai Wu
    Xian-bo Wang
    Ming-xiang Zhang
    Jing-dong Xue
    Yong Li
    Wei Lu
    Jian-chun Guo
    Feng Jiang
    Xin-wei Zhang
    Hong-bo Du
    Xian-zhao Yang
    Hui Guo
    Da-nan Gan
    Zhi-guo Li
    Chinese Journal of Integrative Medicine, 2018, 24 : 653 - 660
  • [36] Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B:Study Protocol for a Multi-Center,Double-Blind Randomized-Controlled Trial
    YE Yong-an
    LI Xiao-ke
    ZHOU Da-qiao
    CHI Xiao-ling
    LI Qin
    WANG Li
    LU Bing-jiu
    MAO De-wen
    WU Qi-kai
    WANG Xian-bo
    ZHANG Ming-xiang
    XUE Jing-dong
    LI Yong
    LU Wei
    GUO Jian-chun
    JIANG Feng
    ZHANG Xin-wei
    DU Hong-bo
    YANG Xian-zhao
    GUO Hui
    GAN Da-nan
    LI Zhi-guo
    Chinese Journal of Integrative Medicine, 2018, 24 (09) : 653 - 660
  • [37] Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
    Liang Dai
    Linda L. D. Zhong
    Yan Cao
    Wei Chen
    Ying Cheng
    Xiu-Fang Lin
    Zhao-Xiang Bian
    Ai-Ping Lu
    Trials, 17
  • [38] Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
    Dai, Liang
    Zhong, Linda L. D.
    Cao, Yan
    Chen, Wei
    Cheng, Ying
    Lin, Xiu-Fang
    Bian, Zhao-Xiang
    Lu, Ai-Ping
    TRIALS, 2016, 17
  • [39] The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in Chronic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
    Yang, Sien-Hung
    Lin, Yi-Hsuan
    Lin, Jr-Rung
    Chen, Hsing-Yu
    Hu, Sindy
    Yang, Yi-Han
    Yang, Yi-Hsun
    Yang, Yin-Shuo
    Fang, Yao-Fan
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [40] The Efficacy and Safety of Milnacipran for Treatment of Fibromyalgiae. A Randomized, Double-blind, Placebo-controlled Trial
    Mease, Philip J.
    Clauw, Daniel J.
    Gendreau, R. Michael
    Rao, Srinivas G.
    Kranzler, Jay
    Chen, Wei
    Palmer, Robert H.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (02) : 398 - 409